x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF
1934
|
Nevada
|
59-2262718
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
incorporation
or organization)
|
Identification
Number)
|
25
Health Sciences Drive, Suite 113
|
|
Stony
Brook, New York
|
11790
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
·
|
Indicate
by check mark whether the registrant (1) filed all reports required
to be
filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during
the last 12 months (or for such shorter period that the registrant
was
required to file such reports), and (2) has been subject to such
filing
requirements for the past 90
days.
|
·
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). |
·
|
The
number of shares of Common Stock, $0.001 par value, outstanding
on August
17, 2007, was approximately
160,499,549.
|
· |
Transitional
Small Business Disclosure Format (check
one):
|
APPLIED
DNA SCIENCES,
INC
|
|||
QUARTERLY
REPORT ON FORM 10-QSB FOR THE
|
|||
QUARTERLY
PERIOD ENDING JUNE 30, 2007
|
|||
Table
of Contents
|
|||
PART I. FINANCIAL INFORMATION | |||
Item 1. Financial Statements | |||
Condensed
Consolidated Balance Sheet: June 30, 2007 (Unaudited)
|
1
|
||
Condensed
Consolidated Statements of Losses:
Three
Months Ended June 30, 2007 and 2006 (Unaudited) and the Period from
September 16, 2002 (Date of Inception) Through June 30, 2007
(Unaudited)
|
2
|
||
Condensed
Consolidated Statement of Stockholder’s Equity (Deficiency):
For
the Period from September 16, 2002 (Date of Inception) Through June
30,
2007 (Unaudited)
|
3
|
||
Condensed
Consolidated Statements of Cash Flows:
Three
Months Ended June 30, 2007 and 2006 (Unaudited) and the Period from
September 16, 2002 (Date of Inception) Through June 30, 2007
(Unaudited)
|
17
|
||
Notes
to Unaudited Condensed Consolidated Financial Information: June 30,
2007
|
19-42
|
||
Item 2. Management’s Discussion and Analysis |
43
|
||
Item 3 Controls and Procedures |
60
|
||
PART II. OTHER INFORMATION | |||
Item 1. Legal Proceedings |
62
|
||
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds |
63
|
||
Item 3. Defaults Upon Senior Securities |
63
|
||
Item 4. Submission of Matters to a Vote of Security Holders |
63
|
||
Item 5. Other Information |
63
|
||
|
Item 6. Exhibits |
63
|
|
Signatures |
64
|
APPLIED
DNA SCIENCES, INC.
|
||||
(A
Development stage company)
|
||||
CONDENSED
CONSOLIDATED BALANCE SHEET
|
||||
(unaudited)
|
||||
June
30,
|
||||
2007
|
||||
ASSETS
|
||||
Current
assets:
|
||||
Cash
|
$
|
34,792
|
||
Prepaid
expenses
|
138,875
|
|||
Total
current assets
|
173,667
|
|||
Property,
plant and equipment-net of accumulated depreciation of
$67,497
|
120,865
|
|||
Other
assets:
|
||||
Deposits
|
13,822
|
|||
Capitalized
finance costs-net of accumulated amortization of
$1,641,988
|
65,612
|
|||
Intangible
assets:
|
||||
Patients,
net of accumulated amortization of $23,732 (Note B)
|
10,525
|
|||
Intellectual
property, net of accumulated amortization and write off of $7,611,943
(Note B)
|
1,818,957
|
|||
Total
Assets
|
$
|
2,203,448
|
||
LIABILITIES
AND DEFICIENCY IN STOCKHOLDERS' EQUITY
|
||||
Current
liabilities:
|
||||
Accounts
payable and accrued liabilities
|
$
|
8,976,675
|
||
Convertible
notes payable, net of unamortized discount (Note D)
|
1,745,855
|
|||
Total
current liabilities
|
10,722,530
|
|||
Debt
derivative and warrant liability
|
4,468,404
|
|||
Commitments
and contingencies (Note J)
|
||||
Deficiency
in Stockholders' Equity- (Note F)
|
||||
Preferred
stock, par value $0.0001 per share; 10,000,000 shares authorized;
60,000
issued and outstanding
|
6
|
|||
Common
stock, par value $0.001 per share; 410,000,000 shares authorized;
160,499,549 issued and outstanding
|
160,499
|
|||
Additional
paid in capital
|
87,420,306
|
|||
Accumulated
deficit
|
(100,568,297
|
)
|
||
Total
deficiency in stockholders' equity
|
(12,987,486
|
)
|
||
Total
liabilities and Deficiency in Stockholders' Equity
|
$
|
2,203,448
|
||
See
the accompanying notes to the consolidated financial
statements
|
APPLIED
DNA SCIENCES, INC.
|
||||||||||||||||
(A
DEVELOPMENT STAGE COMPANY)
|
||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENTS OF LOSSES
|
||||||||||||||||
(unaudited)
|
||||||||||||||||
From
September 16, 2002
|
||||||||||||||||
For
the three months Ended June 30,
|
For
the nine months Ended June 30,
|
(Date
of Inception)
|
||||||||||||||
2007
|
2006
|
2007
|
2006
|
Through
June 30, 2007
|
||||||||||||
RESTATED
|
RESTATED
|
|||||||||||||||
Sales
|
$
|
-
|
$
|
18,900
|
$
|
-
|
$
|
18,900
|
$
|
18,900
|
||||||
Cost
of sales
|
-
|
(15,639
|
)
|
-
|
(15,639
|
)
|
15,639
|
|||||||||
Gross
Profit
|
-
|
3,261
|
-
|
3,261
|
3,261
|
|||||||||||
Operating
expenses:
|
||||||||||||||||
Selling,
general and administrative
|
1,968,642
|
1,580,967
|
6,012,028
|
4,391,305
|
86,077,987
|
|||||||||||
Research
and development
|
25,504
|
-
|
94,289
|
75,276
|
1,124,888
|
|||||||||||
Impairment
of intangible asset(s)
|
-
|
-
|
-
|
-
|
5,655,011
|
|||||||||||
Depreciation
and amortization
|
108,357
|
336,824
|
324,594
|
1,021,199
|
2,054,320
|
|||||||||||
Total
operating expenses
|
2,102,503
|
1,917,791
|
6,430,912
|
5,487,780
|
94,912,207
|
|||||||||||
NET
LOSS FROM OPERATIONS
|
(2,102,503
|
)
|
(1,914,530
|
)
|
(6,430,912
|
)
|
(5,484,519
|
)
|
(94,908,946
|
)
|
||||||
Net
gain (loss) in revaluation of debt derivative and warrant
liabilities
|
4,431,421
|
3,493,961
|
142,131
|
14,250,621
|
33,687,958
|
|||||||||||
Other
income
|
(0
|
)
|
8,483
|
977
|
17,976
|
111,807
|
||||||||||
Interest
expense
|
(520,963
|
)
|
(826,827
|
)
|
(1,945,702
|
)
|
(3,177,229
|
)
|
(39,459,116
|
)
|
||||||
Net
income (loss) before provision for income taxes
|
1,807,954
|
761,087
|
(8,233,506
|
)
|
5,606,849
|
(100,568,297
|
)
|
|||||||||
Income
taxes (benefit)
|
-
|
-
|
-
|
-
|
-
|
|||||||||||
NET
INCOME (LOSS)
|
$
|
1,807,954
|
$
|
761,087
|
$
|
(8,233,506
|
)
|
$
|
5,606,849
|
$
|
(100,568,297
|
)
|
||||
Net
income (loss) per share-basic
|
$
|
0.01
|
$
|
0.01
|
$
|
(0.07
|
)
|
$
|
0.05
|
|||||||
Net
loss per share-assuming fully diluted-Note A
|
$
|
(0.02
|
)
|
$
|
(0.02
|
)
|
$
|
(0.04
|
)
|
|||||||
Weighted
average shares outstanding-
|
||||||||||||||||
Basic
|
132,310,413
|
118,582,385
|
124,844,409
|
115,852,521
|
||||||||||||
Fully
diluted
|
170,056,948
|
177,501,849
|
162,590,944
|
181,716,985
|
||||||||||||
See
the accompanying notes to the consolidated financial
statements
|
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH JUNE
30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Paid
in
|
Common
|
Stock
|
During
|
||||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Common
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
Issuance
of common stock
|
||||||||||||||||||||||||||||
to
Founders in exchange
|
||||||||||||||||||||||||||||
for
services on September
|
||||||||||||||||||||||||||||
16,
2002 at $.01 per share
|
-
|
-
|
100,000
|
$
|
10
|
$
|
990
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
1,000
|
|||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(11,612
|
)
|
(11,612
|
)
|
|||||||||||||||||
Balance
at September 30, 2002
|
-
|
$
|
-
|
100,000
|
$
|
10
|
$
|
990
|
$
|
-
|
$
|
-
|
$
|
(11,612
|
)
|
$
|
(10,612
|
)
|
||||||||||
Issuance
of common stock in
|
||||||||||||||||||||||||||||
connection
with merger with
|
||||||||||||||||||||||||||||
Prohealth
Medical Technologies,
|
||||||||||||||||||||||||||||
Inc
on October 1, 2002
|
-
|
-
|
10,178,352
|
1,015
|
-
|
-
|
-
|
-
|
1,015
|
|||||||||||||||||||
Cancellation
of common stock
|
||||||||||||||||||||||||||||
in
connection with merger with
|
||||||||||||||||||||||||||||
Prohealth
Medical
|
||||||||||||||||||||||||||||
Technologies,
Inc on October
|
||||||||||||||||||||||||||||
21,
2002
|
-
|
-
|
(100,000
|
)
|
(10
|
)
|
(1,000
|
)
|
-
|
-
|
-
|
(1,010
|
)
|
|||||||||||||||
Issuance
of common stock in
|
||||||||||||||||||||||||||||
exchange
for services in
|
||||||||||||||||||||||||||||
October
2002 at $0.65 per
|
||||||||||||||||||||||||||||
share
|
-
|
-
|
602,000
|
60
|
39,070
|
-
|
-
|
-
|
39,130
|
|||||||||||||||||||
Issuance
of common stock in
|
||||||||||||||||||||||||||||
exchange
for subscription in
|
||||||||||||||||||||||||||||
November
and December 2002
|
||||||||||||||||||||||||||||
at
$0.065 per share
|
-
|
-
|
876,000
|
88
|
56,852
|
-
|
(56,940
|
)
|
-
|
-
|
||||||||||||||||||
Cancellation
of common stock
|
||||||||||||||||||||||||||||
in
January 2003 previously
|
||||||||||||||||||||||||||||
issued
in exchange for
|
||||||||||||||||||||||||||||
consulting
services
|
-
|
-
|
(836,000
|
)
|
(84
|
)
|
(54,264
|
)
|
-
|
54,340
|
-
|
(8
|
)
|
|||||||||||||||
Issuance
of common stock in
|
||||||||||||||||||||||||||||
exchange
for licensing services
|
||||||||||||||||||||||||||||
valued
at $0.065 per share in
|
||||||||||||||||||||||||||||
January
2003
|
-
|
-
|
1,500,000
|
150
|
97,350
|
-
|
-
|
-
|
97,500
|
|||||||||||||||||||
Issuance
of common stock in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
valued at $0.13 per
|
||||||||||||||||||||||||||||
share
in January 2003
|
-
|
-
|
586,250
|
58
|
76,155
|
-
|
-
|
-
|
76,213
|
|||||||||||||||||||
Issuance
of common stock in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.065 per share in
|
||||||||||||||||||||||||||||
February
2003
|
-
|
-
|
9,000
|
1
|
584
|
-
|
-
|
-
|
585
|
|||||||||||||||||||
Issuance
of common stock to
|
||||||||||||||||||||||||||||
Founders
in exchange for
|
||||||||||||||||||||||||||||
services
valued at $0.0001 per
|
||||||||||||||||||||||||||||
share
in March 2003
|
-
|
-
|
10,140,000
|
1,014
|
-
|
-
|
-
|
-
|
1,014
|
|||||||||||||||||||
Issuance
of common stock in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
valued at $2.50 per
|
||||||||||||||||||||||||||||
share
in March 2003
|
-
|
-
|
91,060
|
10
|
230,624
|
-
|
-
|
-
|
230,634
|
|||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH JUNE
30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
|
Issuance
of common stock in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
valued
at $0.065 per share in
|
||||||||||||||||||||||||||||
March
2003
|
-
|
-
|
6,000
|
1
|
389
|
-
|
-
|
-
|
390
|
|||||||||||||||||||
Common
stock subscribed in
|
||||||||||||||||||||||||||||
exchange
for cash at $1 per
|
||||||||||||||||||||||||||||
share
in March 2003
|
-
|
-
|
-
|
-
|
18,000
|
-
|
-
|
-
|
18,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.065 per
|
||||||||||||||||||||||||||||
share
on April 1, 2003
|
-
|
-
|
860,000
|
86
|
55,814
|
-
|
-
|
-
|
55,900
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for cash at $1.00 per
|
||||||||||||||||||||||||||||
share
on April 9, 2003
|
-
|
-
|
18,000
|
2
|
-
|
-
|
-
|
-
|
2
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.065 per share on April 9,
|
||||||||||||||||||||||||||||
2003
|
-
|
-
|
9,000
|
1
|
584
|
-
|
-
|
-
|
585
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$2.50 per share on April 23,
|
||||||||||||||||||||||||||||
2003
|
-
|
-
|
5,000
|
1
|
12,499
|
-
|
-
|
-
|
12,500
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$2.50 per share, on June 12,
|
||||||||||||||||||||||||||||
2003
|
-
|
-
|
10,000
|
1
|
24,999
|
-
|
-
|
-
|
25,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for cash at $1.00 per
|
||||||||||||||||||||||||||||
share
on June 17, 2003
|
-
|
-
|
50,000
|
5
|
49,995
|
-
|
-
|
-
|
50,000
|
|||||||||||||||||||
Common
stock subscribed in
|
||||||||||||||||||||||||||||
exchange
for cash at $2.50 per
|
||||||||||||||||||||||||||||
share
pursuant to a private
|
||||||||||||||||||||||||||||
placement
on June 27, 2003
|
-
|
-
|
-
|
-
|
-
|
24,000
|
-
|
-
|
24,000
|
|||||||||||||||||||
Common
stock retired in
|
||||||||||||||||||||||||||||
exchange
for note payable
|
||||||||||||||||||||||||||||
at
$0.0118 per share,
|
||||||||||||||||||||||||||||
in
June 30, 2003
|
-
|
-
|
(7,500,000
|
)
|
(750
|
)
|
750
|
-
|
-
|
-
|
-
|
|||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.065 per share, on June 30,
|
||||||||||||||||||||||||||||
2003
|
-
|
-
|
270,000
|
27
|
17,523
|
-
|
-
|
-
|
17,550
|
|||||||||||||||||||
Common
stock subscribed in
|
||||||||||||||||||||||||||||
exchange
for cash at $1.00 per
|
||||||||||||||||||||||||||||
share
pursuant to a private
|
||||||||||||||||||||||||||||
placement
on June 30, 2003
|
-
|
-
|
-
|
-
|
-
|
10,000
|
-
|
-
|
10,000
|
|||||||||||||||||||
Common
stock subscribed in
|
||||||||||||||||||||||||||||
exchange
for cash at $2.50 per
|
||||||||||||||||||||||||||||
share
pursuant to a private
|
||||||||||||||||||||||||||||
placement
on June 30, 2003
|
-
|
-
|
-
|
-
|
-
|
24,000
|
-
|
-
|
24,000
|
|||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH JUNE
30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
approximately $2.01 per
|
||||||||||||||||||||||||||||
share,
July 2003
|
-
|
-
|
213,060
|
21
|
428,798
|
-
|
-
|
-
|
428,819
|
|||||||||||||||||||
Common
stock canceled in July
|
||||||||||||||||||||||||||||
2003,
previously issued for
|
||||||||||||||||||||||||||||
services
rendered at $2.50 per
|
||||||||||||||||||||||||||||
share
|
-
|
-
|
(24,000
|
)
|
(2
|
)
|
(59,998
|
)
|
-
|
-
|
-
|
(60,000
|
)
|
|||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for options exercised
|
||||||||||||||||||||||||||||
at
$1.00 per share in July 2003
|
-
|
-
|
20,000
|
2
|
19,998
|
-
|
-
|
-
|
20,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for exercise of
|
||||||||||||||||||||||||||||
options
previously subscribed at
|
||||||||||||||||||||||||||||
$1.00
per share in July 2003
|
-
|
-
|
10,000
|
1
|
9,999
|
(10,000
|
)
|
-
|
-
|
-
|
||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
approximately $2.38 per
|
||||||||||||||||||||||||||||
Share
in August 2003
|
-
|
-
|
172,500
|
17
|
410,915
|
-
|
-
|
-
|
410,932
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for options exercised
|
||||||||||||||||||||||||||||
at
$1.00 per share in August 2003
|
-
|
-
|
29,000
|
3
|
28,997
|
-
|
-
|
-
|
29,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
approximately $2.42 per
|
||||||||||||||||||||||||||||
share
in September 2003
|
-
|
-
|
395,260
|
40
|
952,957
|
-
|
-
|
-
|
952,997
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for cash at $2.50 per
|
||||||||||||||||||||||||||||
share-subscription
|
||||||||||||||||||||||||||||
payable
in September 2003
|
-
|
-
|
19,200
|
2
|
47,998
|
(48,000
|
)
|
-
|
-
|
-
|
||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for cash at $2.50 per
|
||||||||||||||||||||||||||||
share
pursuant to a private
|
||||||||||||||||||||||||||||
placement
in September 2003
|
-
|
-
|
6,400
|
1
|
15,999
|
-
|
-
|
-
|
16,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for options exercised
|
||||||||||||||||||||||||||||
at
$1.00 per share in September 2003
|
-
|
-
|
95,000
|
10
|
94,991
|
-
|
-
|
-
|
95,001
|
|||||||||||||||||||
Common
stock subscription
|
||||||||||||||||||||||||||||
receivable
reclassification
|
||||||||||||||||||||||||||||
adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
2,600
|
-
|
2,600
|
|||||||||||||||||||
Common
Stock subscribed to
|
||||||||||||||||||||||||||||
at
$2.50 per share in September
|
||||||||||||||||||||||||||||
2003
|
-
|
-
|
-
|
-
|
-
|
300,000
|
-
|
-
|
300,000
|
|||||||||||||||||||
Net
Loss for the year
|
||||||||||||||||||||||||||||
ended
September 30, 2003
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(3,445,164
|
)
|
(3,445,164
|
)
|
|||||||||||||||||
Balance
at September 30, 2003
|
-
|
$
|
-
|
17,811,082
|
$
|
1,781
|
$
|
2,577,568
|
$
|
300,000
|
$
|
-
|
$
|
(3,456,776
|
)
|
$
|
(577,427
|
)
|
||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH JUNE
30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Preferred
shares issued in
|
||||||||||||||||||||||||||||
exchange
for services at $25.00
|
||||||||||||||||||||||||||||
per
share in October 2003
|
15,000
|
15
|
-
|
-
|
-
|
-
|
-
|
-
|
15
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
approximately $2.85 per
|
||||||||||||||||||||||||||||
Share
in October 2003
|
-
|
-
|
287,439
|
29
|
820,389
|
-
|
-
|
-
|
820,418
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for cash at $2.50 per
|
||||||||||||||||||||||||||||
share-subscription
|
||||||||||||||||||||||||||||
payable
in October 2003
|
-
|
-
|
120,000
|
12
|
299,988
|
(300,000
|
)
|
-
|
-
|
-
|
||||||||||||||||||
Common
stock canceled in
|
||||||||||||||||||||||||||||
October
2003, previously issued
|
||||||||||||||||||||||||||||
for
services rendered at $2.50
|
||||||||||||||||||||||||||||
per
share
|
-
|
-
|
(100,000
|
)
|
(10
|
)
|
(249,990
|
)
|
-
|
-
|
-
|
(250,000
|
)
|
|||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
approximately $3 per share in
|
||||||||||||||||||||||||||||
November
2003
|
-
|
-
|
100,000
|
10
|
299,990
|
-
|
-
|
-
|
300,000
|
|||||||||||||||||||
Common
stock subscribed in
|
||||||||||||||||||||||||||||
exchange
for cash at $2.50 per
|
||||||||||||||||||||||||||||
share
pursuant to a private
|
||||||||||||||||||||||||||||
placement
in November, 2003
|
-
|
-
|
100,000
|
10
|
249,990
|
-
|
-
|
-
|
250,000
|
|||||||||||||||||||
Common
stock subscribed in
|
||||||||||||||||||||||||||||
exchange
for cash at $2.50 per
|
||||||||||||||||||||||||||||
share
pursuant to a private
|
||||||||||||||||||||||||||||
placement
in December, 2003
|
-
|
-
|
6,400
|
1
|
15,999
|
-
|
-
|
-
|
16,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
approximately $2.59 per
|
||||||||||||||||||||||||||||
share
in December 2003
|
-
|
-
|
2,125,500
|
213
|
5,504,737
|
-
|
-
|
-
|
5,504,950
|
|||||||||||||||||||
Common
Stock subscribed to
|
||||||||||||||||||||||||||||
at
$2.50 per share in December 2003
|
||||||||||||||||||||||||||||
|
-
|
-
|
-
|
-
|
104,000
|
-
|
-
|
104,000
|
||||||||||||||||||||
Beneficial
conversion feature
|
||||||||||||||||||||||||||||
relating
to notes payable
|
-
|
-
|
-
|
-
|
1,168,474
|
-
|
-
|
-
|
1,168,474
|
|||||||||||||||||||
Beneficial
conversion feature
|
||||||||||||||||||||||||||||
relating
to warrants
|
-
|
-
|
-
|
-
|
206,526
|
-
|
-
|
-
|
206,526
|
|||||||||||||||||||
Adjust
common stock par value
|
||||||||||||||||||||||||||||
from
$0.0001 to $0.50 per share,
|
||||||||||||||||||||||||||||
per
amendment of articles dated
|
||||||||||||||||||||||||||||
in
December 2004
|
-
|
-
|
-
|
10,223,166
|
(10,223,166
|
)
|
-
|
-
|
-
|
-
|
||||||||||||||||||
Common
Stock issued pursuant
|
||||||||||||||||||||||||||||
to
subscription at $2.50 share
|
||||||||||||||||||||||||||||
in
January 2004
|
-
|
-
|
41,600
|
20,800
|
83,200
|
(104,000
|
)
|
-
|
-
|
-
|
||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH JUNE
30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$2.95 per share in January 2004
|
-
|
-
|
13,040
|
6,520
|
31,948
|
-
|
-
|
-
|
38,468
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$2.60 per share in January 2004
|
-
|
-
|
123,000
|
61,500
|
258,300
|
-
|
-
|
-
|
319,800
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$3.05 per share in January 2004
|
-
|
-
|
1,000
|
500
|
2,550
|
-
|
-
|
-
|
3,050
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for employee services
|
||||||||||||||||||||||||||||
at
$3.07 per share in February 2004
|
-
|
-
|
6,283
|
3,142
|
16,147
|
-
|
-
|
-
|
19,289
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$3.04 per share in March 2004
|
-
|
-
|
44,740
|
22,370
|
113,640
|
-
|
-
|
-
|
136,010
|
|||||||||||||||||||
Common
Stock issued for
|
||||||||||||||||||||||||||||
options
exercised at $1.00 per
|
||||||||||||||||||||||||||||
share
in March 2004
|
-
|
-
|
55,000
|
27,500
|
27,500
|
-
|
-
|
-
|
55,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for employee services
|
||||||||||||||||||||||||||||
at
$3.00 per share in March 2004
|
-
|
-
|
5,443
|
2,722
|
13,623
|
-
|
-
|
-
|
16,345
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for employee services
|
||||||||||||||||||||||||||||
at
$3.15 per share in March 2004
|
-
|
-
|
5,769
|
2,885
|
15,292
|
-
|
-
|
-
|
18,177
|
|||||||||||||||||||
Preferred
shared converted to
|
||||||||||||||||||||||||||||
common
shares for consulting
|
||||||||||||||||||||||||||||
services
at $3.00 per share in
|
||||||||||||||||||||||||||||
March
2004
|
(5,000
|
)
|
(5
|
)
|
125,000
|
62,500
|
312,500
|
-
|
-
|
-
|
374,995
|
|||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for employee services
|
||||||||||||||||||||||||||||
at
$3.03 per share in March 2004
|
-
|
-
|
8,806
|
4,400
|
22,238
|
-
|
-
|
-
|
26,638
|
|||||||||||||||||||
Common
Stock issued pursuant
|
||||||||||||||||||||||||||||
to
subscription at $2.50 per
|
||||||||||||||||||||||||||||
share
in March 2004
|
-
|
-
|
22,500
|
11,250
|
(9,000
|
)
|
-
|
-
|
-
|
2,250
|
||||||||||||||||||
Beneficial
Conversion Feature
|
||||||||||||||||||||||||||||
relating
to Notes Payable
|
-
|
-
|
122,362
|
-
|
-
|
-
|
122,362
|
|||||||||||||||||||||
Beneficial
Conversion Feature
|
-
|
-
|
||||||||||||||||||||||||||
relating
to Warrants
|
-
|
-
|
177,638
|
-
|
-
|
-
|
177,638
|
|||||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$2.58 per share in April 2004
|
-
|
-
|
9,860
|
4,930
|
20,511
|
-
|
-
|
-
|
25,441
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$2.35 per share in April 2004
|
-
|
-
|
11,712
|
5,856
|
21,667
|
-
|
-
|
-
|
27,523
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$1.50 per share in April 2004
|
-
|
-
|
367,500
|
183,750
|
367,500
|
-
|
-
|
-
|
551,250
|
|||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH JUNE
30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Common
stock returned to
|
||||||||||||||||||||||||||||
treasury
at $0.065 per share in
|
||||||||||||||||||||||||||||
April
2004
|
-
|
-
|
(50,000
|
)
|
(25,000
|
)
|
21,750
|
-
|
-
|
-
|
(3,250
|
)
|
||||||||||||||||
Preferred
stock converted to
|
||||||||||||||||||||||||||||
common
stock for consulting
|
||||||||||||||||||||||||||||
services
at $1.01 per share
|
||||||||||||||||||||||||||||
in
May 2004
|
(4,000
|
)
|
(4
|
)
|
100,000
|
50,000
|
51,250
|
-
|
-
|
-
|
101,246
|
|||||||||||||||||
Common
stock issued per
|
||||||||||||||||||||||||||||
subscription
in May 2004
|
-
|
-
|
10,000
|
5,000
|
(4,000
|
)
|
-
|
(1,000
|
)
|
-
|
-
|
|||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.86 per
|
||||||||||||||||||||||||||||
share
in May 2004
|
-
|
-
|
137,000
|
68,500
|
50,730
|
-
|
- |
-
|
119,230
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $1.15 per
|
||||||||||||||||||||||||||||
share
in May 2004
|
-
|
-
|
26,380
|
13,190
|
17,147
|
-
|
- |
-
|
30,337
|
|||||||||||||||||||
Common
stock returned to
|
||||||||||||||||||||||||||||
treasury
at $0.065 per
|
||||||||||||||||||||||||||||
share
in June 2004
|
-
|
-
|
(5,000
|
)
|
(2,500
|
)
|
2,175
|
-
|
- |
-
|
(325
|
)
|
||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.67 per
|
||||||||||||||||||||||||||||
share
in June 2004
|
-
|
-
|
270,500
|
135,250
|
45,310
|
-
|
- |
-
|
180,560
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.89 per share in June 2004
|
-
|
-
|
8,000
|
4,000
|
3,120
|
-
|
-
|
-
|
7,120
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.65 per share in June 2004
|
-
|
-
|
50,000
|
25,000
|
7,250
|
-
|
-
|
-
|
32,250
|
|||||||||||||||||||
Common
stock issued pursuant
|
||||||||||||||||||||||||||||
to
a private placement at $1.00
|
||||||||||||||||||||||||||||
per
share in June 2004
|
-
|
-
|
250,000
|
125,000
|
125,000
|
-
|
-
|
-
|
250,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.54 per share in July 2004
|
-
|
-
|
100,000
|
50,000
|
4,000
|
-
|
-
|
-
|
54,000
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.72 per share in July 2004
|
-
|
-
|
5,000
|
2,500
|
1,100
|
-
|
-
|
-
|
3,600
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.47 per share in July 2004
|
-
|
-
|
100,000
|
50,000
|
(2,749
|
)
|
-
|
-
|
-
|
47,251
|
||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.39 per
|
||||||||||||||||||||||||||||
share
in August 2004
|
-
|
-
|
100,000
|
50,000
|
(11,000
|
)
|
-
|
-
|
-
|
39,000
|
||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
JUNE 30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Preferred
stock converted
|
||||||||||||||||||||||||||||
to
common stock for
|
||||||||||||||||||||||||||||
consulting
services at
|
||||||||||||||||||||||||||||
$0.39
per share in August 2004
|
(2,000
|
)
|
(2
|
)
|
50,000
|
25,000
|
(5,500
|
)
|
-
|
-
|
-
|
19,498
|
||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.50 per
|
||||||||||||||||||||||||||||
share
in August 2004
|
-
|
-
|
100,000
|
50,000
|
250
|
-
|
-
|
-
|
50,250
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.56 per
|
||||||||||||||||||||||||||||
share
in August 2004
|
-
|
-
|
200,000
|
100,000
|
12,500
|
-
|
-
|
-
|
112,500
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.41 per
|
||||||||||||||||||||||||||||
share
in August 2004
|
-
|
-
|
92,500
|
46,250
|
(8,605
|
)
|
-
|
-
|
-
|
37,645
|
||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.52 per
|
||||||||||||||||||||||||||||
share
in September 2004
|
-
|
-
|
1,000,000
|
500,000
|
17,500
|
-
|
-
|
-
|
517,500
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.46 per
|
||||||||||||||||||||||||||||
share
in September 2004
|
-
|
-
|
5,000
|
2,500
|
(212
|
)
|
-
|
-
|
-
|
2,288
|
||||||||||||||||||
Common
stock issued pursuant
|
||||||||||||||||||||||||||||
to
subscription at $0.50 per
|
||||||||||||||||||||||||||||
share
in September 2004
|
-
|
-
|
40,000
|
20,000
|
-
|
-
|
-
|
-
|
20,000
|
|||||||||||||||||||
Preferred
shares converted to
|
||||||||||||||||||||||||||||
common
stock for consulting
|
||||||||||||||||||||||||||||
services
at $0.41 per share in
|
||||||||||||||||||||||||||||
September
2004
|
(4,000
|
)
|
(4
|
)
|
100,000
|
50,000
|
4,000
|
-
|
-
|
-
|
53,996
|
|||||||||||||||||
Preferred
shares issued in
|
||||||||||||||||||||||||||||
exchange
for service at $25 per
|
||||||||||||||||||||||||||||
share
in September 2004
|
60,000
|
6
|
-
|
-
|
1,499,994
|
-
|
-
|
-
|
1,500,000
|
|||||||||||||||||||
Fair
value of 2,841,000 warrants
|
||||||||||||||||||||||||||||
issued
to non-employees and
|
||||||||||||||||||||||||||||
consultants
for services rendered
|
||||||||||||||||||||||||||||
at
approximately $0.71 per warrant
|
||||||||||||||||||||||||||||
in
September 2004
|
-
|
-
|
-
|
-
|
2,019,862
|
-
|
-
|
-
|
2,019,862
|
|||||||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(19,358,258
|
)
|
(19,358,258
|
)
|
|||||||||||||||||
Balance
at September 30, 2004
|
60,000
|
$
|
6
|
23,981,054
|
$
|
11,990,527
|
$
|
6,118,993
|
$
|
-
|
$
|
(1,000
|
)
|
$
|
(22,815,034
|
)
|
$
|
(4,706,508
|
)
|
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
JUNE 30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.68 per share in October 2004
|
-
|
-
|
200,000
|
100,000
|
36,000
|
-
|
-
|
-
|
136,000
|
|||||||||||||||||||
Common
stock returned
|
||||||||||||||||||||||||||||
to
treasury at $0.60 per share
|
||||||||||||||||||||||||||||
in
October 2004
|
-
|
-
|
(1,069,600
|
)
|
(534,800
|
)
|
(107,297
|
)
|
-
|
-
|
-
|
(642,097
|
)
|
|||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.60 per share in October 2004
|
-
|
-
|
82,500
|
41,250
|
8,250
|
-
|
-
|
-
|
49,500
|
|||||||||||||||||||
Common
Stock issued pursuant
|
||||||||||||||||||||||||||||
to
subscription at $0.60 per share
|
||||||||||||||||||||||||||||
in
October 2004
|
-
|
-
|
500,000
|
250,000
|
50,000
|
(300,000
|
)
|
-
|
-
|
-
|
||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.50 per share in October 2004
|
-
|
-
|
532,500
|
266,250
|
-
|
-
|
-
|
-
|
266,250
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for debt at $0.50 per
|
||||||||||||||||||||||||||||
share
in October 2004
|
-
|
-
|
500,000
|
250,000
|
-
|
-
|
-
|
-
|
250,000
|
|||||||||||||||||||
Common
Stock issued pursuant
|
||||||||||||||||||||||||||||
to
subscription at $0.45 per share
|
||||||||||||||||||||||||||||
in
October 2004
|
-
|
-
|
1,000,000
|
500,000
|
(50,000
|
)
|
(450,000
|
)
|
-
|
-
|
-
|
|||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.45 per share in October 2004
|
-
|
-
|
315,000
|
157,500
|
(15,750
|
)
|
-
|
-
|
-
|
141,750
|
||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.47 per share
|
||||||||||||||||||||||||||||
in
November 2004
|
-
|
-
|
100,000
|
50,000
|
(3,000
|
)
|
-
|
-
|
-
|
47,000
|
||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.8 0 per share
|
||||||||||||||||||||||||||||
in
November 2004
|
-
|
-
|
300,000
|
150,000
|
90,000
|
-
|
-
|
-
|
240,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $1.44 per share
|
||||||||||||||||||||||||||||
in
November 2004
|
-
|
-
|
115,000
|
57,500
|
108,100
|
-
|
-
|
-
|
165,600
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for employee
|
||||||||||||||||||||||||||||
services
at $1.44 per share
|
||||||||||||||||||||||||||||
in
November 2004
|
-
|
-
|
5,000
|
2,500
|
4,700
|
-
|
-
|
-
|
7,200
|
|||||||||||||||||||
Warrants
exercised
|
||||||||||||||||||||||||||||
at
$0.60 per share
|
||||||||||||||||||||||||||||
in
November 2004
|
-
|
-
|
60,000
|
30,000
|
6,000
|
(4,000
|
)
|
-
|
-
|
32,000
|
||||||||||||||||||
Beneficial
Conversion discount
|
||||||||||||||||||||||||||||
relating
to Notes Payable
|
-
|
-
|
-
|
-
|
1,465,000
|
-
|
-
|
-
|
1,465,000
|
|||||||||||||||||||
Common
stock issued at $0.016
|
||||||||||||||||||||||||||||
per
share in exchange for note
|
||||||||||||||||||||||||||||
payable
in December 2004
|
-
|
-
|
5,500,000
|
2,750,000
|
(2,661,500
|
)
|
-
|
-
|
-
|
88,500
|
||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
settlement
of debt at $0.50 per
|
||||||||||||||||||||||||||||
share
in December 2004
|
-
|
-
|
2,930,000
|
1,465,000
|
-
|
(125,000
|
)
|
-
|
-
|
1,340,000
|
||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
JUNE 30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Fair
value of 6,063,500 warrants
|
||||||||||||||||||||||||||||
issued
to non employees and
|
||||||||||||||||||||||||||||
consultants
for services rendered
|
||||||||||||||||||||||||||||
at
$0.52 per warrant in October
|
||||||||||||||||||||||||||||
and
December 2004
|
-
|
-
|
-
|
-
|
3,169,052
|
-
|
-
|
-
|
3,169,052
|
|||||||||||||||||||
Warrants
exercised at $0.10 per
|
||||||||||||||||||||||||||||
share
in January 2005
|
-
|
-
|
25,000
|
12,500
|
(10,000
|
)
|
-
|
-
|
-
|
2,500
|
||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
settlement
of debt at $0.33 per
|
||||||||||||||||||||||||||||
share
in January 2005
|
-
|
-
|
1,628,789
|
814,395
|
(276,895
|
)
|
-
|
-
|
-
|
537,500
|
||||||||||||||||||
Warrants
exercised at $0.10 per
|
||||||||||||||||||||||||||||
share
in January 2005
|
-
|
-
|
17,500
|
8,750
|
(7,000
|
)
|
-
|
-
|
-
|
1,750
|
||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
settlement
of debt at $0.33 per
|
||||||||||||||||||||||||||||
share
in January 2005
|
-
|
-
|
2,399,012
|
1,199,504
|
(407,830
|
)
|
-
|
-
|
-
|
791,674
|
||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $1.30 per share
|
-
|
-
|
315,636
|
157,818
|
252,508
|
-
|
-
|
-
|
410,326
|
|||||||||||||||||||
in
January 2005
|
||||||||||||||||||||||||||||
Fair
value of warrant liability
|
||||||||||||||||||||||||||||
reclassed
due to registration rights
|
||||||||||||||||||||||||||||
granted
in February 2005
|
-
|
-
|
-
|
-
|
(3,108,851
|
)
|
-
|
-
|
-
|
(3,108,851
|
)
|
|||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $1.44 per share
|
||||||||||||||||||||||||||||
in
February 2005
|
-
|
-
|
5,796,785
|
2,898,393
|
5,418,814
|
-
|
-
|
-
|
8,317,207
|
|||||||||||||||||||
Fair
value of 55,000 warrants issued
|
||||||||||||||||||||||||||||
to
consultants for services at $1.31
|
||||||||||||||||||||||||||||
per
warrant in February 2005
|
-
|
-
|
-
|
-
|
72,017
|
-
|
-
|
-
|
72,017
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
settlement
of debt at $0.33 per
|
||||||||||||||||||||||||||||
share
in February 2005
|
-
|
-
|
75,757
|
37,879
|
(12,879
|
)
|
-
|
-
|
-
|
25,000
|
||||||||||||||||||
Warrants
exercised at $0.10 per
|
||||||||||||||||||||||||||||
share
in February 2005
|
-
|
-
|
20,000
|
10,000
|
(8,000
|
)
|
-
|
-
|
-
|
2,000
|
||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
settlement
of debt at $0.33 per
|
||||||||||||||||||||||||||||
share
in February 2005
|
-
|
-
|
606,060
|
303,030
|
(103,030
|
)
|
-
|
-
|
-
|
200,000
|
||||||||||||||||||
Warrants
exercised at $0.10 per
|
||||||||||||||||||||||||||||
share
in February 2005
|
-
|
-
|
45,000
|
22,500
|
(18,000
|
)
|
-
|
-
|
-
|
4,500
|
||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for related party debt
|
||||||||||||||||||||||||||||
at
$1.31 per share in February
|
||||||||||||||||||||||||||||
2005
|
-
|
-
|
1,500,000
|
750,000
|
1,215,000
|
-
|
-
|
-
|
1,965,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
settlement
of debt at $0.33 per
|
||||||||||||||||||||||||||||
share
in February 2005
|
-
|
-
|
278,433
|
139,217
|
(47,334
|
)
|
-
|
-
|
-
|
91,883
|
||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
JUNE 30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$1.17 per share in February
|
||||||||||||||||||||||||||||
2005
|
-
|
-
|
17,236
|
8,618
|
11,548
|
-
|
-
|
-
|
20,166
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for debt at $0.50 per
|
||||||||||||||||||||||||||||
share
in February 2005
|
-
|
-
|
300,000
|
150,000
|
-
|
-
|
-
|
-
|
150,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.95 per share
|
||||||||||||||||||||||||||||
in
February 2005
|
-
|
-
|
716,500
|
358,250
|
322,425
|
-
|
-
|
-
|
680,675
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.95 per share
|
||||||||||||||||||||||||||||
in
February 2005
|
-
|
-
|
10,500
|
5,250
|
4,725
|
-
|
-
|
-
|
9,975
|
|||||||||||||||||||
Common
stock issued in
|
||||||||||||||||||||||||||||
exchange
for debt at $0.50 per
|
||||||||||||||||||||||||||||
share
in March 2005
|
-
|
-
|
13,202,000
|
6,601,000
|
-
|
-
|
-
|
-
|
6,601,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $1.19 per share
|
||||||||||||||||||||||||||||
in
March 2005
|
-
|
-
|
185,000
|
92,500
|
127,650
|
-
|
-
|
-
|
220,150
|
|||||||||||||||||||
Options
exercised at $0.60 per
|
||||||||||||||||||||||||||||
share
in March 2005
|
-
|
-
|
100,000
|
50,000
|
10,000
|
-
|
-
|
-
|
60,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.98 per share
|
||||||||||||||||||||||||||||
in
March 2005
|
-
|
-
|
1,675,272
|
837,636
|
804,131
|
-
|
-
|
-
|
1,641,767
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.92 per share
|
||||||||||||||||||||||||||||
in
March 2005
|
-
|
-
|
24,333
|
12,167
|
10,219
|
-
|
-
|
-
|
22,386
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.99 per share
|
||||||||||||||||||||||||||||
in
March 2005
|
-
|
-
|
15,000
|
7,500
|
7,350
|
-
|
-
|
-
|
14,850
|
|||||||||||||||||||
Common
stock issued in exchange
|
||||||||||||||||||||||||||||
for
debt at $0.50 per share
|
||||||||||||||||||||||||||||
in
March 2005
|
-
|
-
|
1,240,000
|
620,000
|
-
|
-
|
-
|
-
|
620,000
|
|||||||||||||||||||
Common
stock canceled for
|
||||||||||||||||||||||||||||
shares
issued in exchange of
|
||||||||||||||||||||||||||||
debt
in March 2005
|
-
|
-
|
(500,000
|
)
|
(250,000
|
)
|
-
|
-
|
-
|
-
|
(250,000
|
)
|
||||||||||||||||
Common
stock subscribed
|
||||||||||||||||||||||||||||
canceled
in March 2005
|
-
|
-
|
-
|
-
|
-
|
750,000
|
-
|
-
|
750,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.89 per share
|
||||||||||||||||||||||||||||
in
March 2005
|
-
|
-
|
10,000
|
5,000
|
3,900
|
-
|
-
|
-
|
8,900
|
|||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
JUNE 30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Adjust
common stock par value
|
||||||||||||||||||||||||||||
from
$0.50 to $0.001 per share,
|
||||||||||||||||||||||||||||
per
amendment of Articles of
|
||||||||||||||||||||||||||||
Incorporation
in March-05
|
-
|
-
|
-
|
(32,312,879
|
)
|
32,312,879
|
-
|
-
|
-
|
-
|
||||||||||||||||||
Beneficial
Conversion discount
|
||||||||||||||||||||||||||||
relating
to Notes Payable in
|
||||||||||||||||||||||||||||
March
2005
|
-
|
-
|
-
|
-
|
7,371,000
|
-
|
-
|
-
|
7,371,000
|
|||||||||||||||||||
Stock
options granted to
|
||||||||||||||||||||||||||||
employees
in exchange for
|
||||||||||||||||||||||||||||
services
rendered, at exercise
|
||||||||||||||||||||||||||||
price
below fair value of common
|
||||||||||||||||||||||||||||
stock
in March 2005
|
-
|
-
|
-
|
-
|
180,000
|
-
|
-
|
-
|
180,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.80 per share in April 2005
|
-
|
-
|
160,000
|
160
|
127,840
|
-
|
-
|
-
|
128,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.80 per share in April 2005
|
-
|
-
|
40,000
|
40
|
31,960
|
-
|
-
|
-
|
32,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.75 per share in April 2005
|
-
|
-
|
850,000
|
850
|
636,650
|
-
|
-
|
-
|
637,500
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.33 per share in April 2005
|
-
|
-
|
500,000
|
500
|
164,500
|
-
|
-
|
-
|
165,000
|
|||||||||||||||||||
Common
Stock canceled during
|
||||||||||||||||||||||||||||
April
2005, previously issued for
|
||||||||||||||||||||||||||||
services
rendered at $3.42 per
|
||||||||||||||||||||||||||||
share
|
-
|
-
|
(10,000
|
)
|
(10
|
)
|
(34,190
|
)
|
-
|
-
|
-
|
(34,200
|
)
|
|||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
settlement
of debt at $0.33 per
|
||||||||||||||||||||||||||||
share
in April 2005
|
-
|
-
|
75,758
|
77
|
24,923
|
(25,000
|
)
|
-
|
-
|
-
|
||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.68 per share in April 2005
|
-
|
-
|
50,000
|
50
|
33,950
|
-
|
-
|
-
|
34,000
|
|||||||||||||||||||
Proceeds
received against
|
||||||||||||||||||||||||||||
subscription
payable in June
|
||||||||||||||||||||||||||||
2005
|
-
|
-
|
-
|
-
|
-
|
118,000
|
-
|
-
|
118,000
|
|||||||||||||||||||
Common
Stock canceled in
|
||||||||||||||||||||||||||||
June
2005, previously issued for
|
||||||||||||||||||||||||||||
services
rendered at $0.50 per
|
||||||||||||||||||||||||||||
share
|
-
|
-
|
(10,000
|
)
|
(10
|
)
|
(4,990
|
)
|
-
|
-
|
-
|
(5,000
|
)
|
|||||||||||||||
Cancellation
of previously
|
||||||||||||||||||||||||||||
granted
stock options granted
|
||||||||||||||||||||||||||||
to
employees for services
|
||||||||||||||||||||||||||||
rendered,
at exercise price
|
||||||||||||||||||||||||||||
below
fair value of common stock
|
-
|
-
|
-
|
-
|
(180,000
|
)
|
-
|
-
|
-
|
(180,000
|
)
|
|||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
JUNE 30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.60 per share in July 2005
|
-
|
-
|
157,000
|
157
|
94,043
|
-
|
-
|
-
|
94,200
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for intellectual property
|
||||||||||||||||||||||||||||
at
$0.67 per share in July 2005
|
-
|
-
|
36,000,000
|
36,000
|
24,084,000
|
-
|
-
|
-
|
24,120,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.60 per share
|
||||||||||||||||||||||||||||
in
July 2005
|
-
|
-
|
640,000
|
640
|
383,360
|
-
|
-
|
-
|
384,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for employee services
|
||||||||||||||||||||||||||||
at
$0.48 per share in July 2005
|
-
|
-
|
8,000,000
|
8,000
|
3,832,000
|
-
|
-
|
-
|
3,840,000
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.94 per share
|
||||||||||||||||||||||||||||
in
July 2005
|
-
|
-
|
121,985
|
121
|
168,217
|
-
|
-
|
-
|
168,338
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.48 per share
|
||||||||||||||||||||||||||||
in
August 2005
|
-
|
-
|
250,000
|
250
|
119,750
|
-
|
-
|
-
|
120,000
|
|||||||||||||||||||
Common
Stock penalty shares
|
||||||||||||||||||||||||||||
issued
pursuant to pending SB-2
|
||||||||||||||||||||||||||||
registration
at $0.62 per share in
|
||||||||||||||||||||||||||||
September
2005
|
-
|
-
|
814,158
|
814
|
501,858
|
-
|
-
|
-
|
502,672
|
|||||||||||||||||||
Common
Stock penalty shares
|
||||||||||||||||||||||||||||
issued
pursuant to pending SB-2
|
||||||||||||||||||||||||||||
registration
at $0.70 per share in
|
||||||||||||||||||||||||||||
September
2005
|
-
|
-
|
391,224
|
391
|
273,466
|
-
|
-
|
-
|
273,857
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.94 per share
|
||||||||||||||||||||||||||||
in
September 2005
|
-
|
-
|
185,000
|
185
|
173,715
|
-
|
-
|
-
|
173,900
|
|||||||||||||||||||
Common
Stock returned in
|
||||||||||||||||||||||||||||
September
2005, previously
|
||||||||||||||||||||||||||||
issued
for services rendered at
|
||||||||||||||||||||||||||||
$0.40
per share
|
-
|
-
|
(740,000
|
)
|
(740
|
)
|
(453,232
|
)
|
56,000
|
1,000
|
-
|
(396,972
|
)
|
|||||||||||||||
Net
Loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(67,109,519
|
)
|
(67,109,519
|
)
|
|||||||||||||||||
Balance
as of September
|
||||||||||||||||||||||||||||
30,
2005
|
60,000
|
$
|
6
|
112,230,392
|
$
|
112,230
|
$
|
82,320,715
|
$
|
20,000
|
$
|
-
|
$
|
(89,924,553
|
)
|
$
|
(7,471,602
|
)
|
||||||||||
Common
stock issued in
exchange
for services
|
||||||||||||||||||||||||||||
at
$0.50 per share
|
||||||||||||||||||||||||||||
in
October 2005
|
-
|
-
|
400,000
|
400
|
199,600
|
-
|
-
|
-
|
200,000
|
|||||||||||||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
JUNE 30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting
|
||||||||||||||||||||||||||||
services
at $0.75 per share
|
||||||||||||||||||||||||||||
in
October 2005
|
-
|
-
|
100,000
|
100
|
74,900
|
-
|
-
|
-
|
75,000
|
|||||||||||||||||||
Common
Stock returned in
|
||||||||||||||||||||||||||||
October
2005, previously
|
||||||||||||||||||||||||||||
issued
for services
|
||||||||||||||||||||||||||||
rendered
at $0.60 per share
|
-
|
-
|
(350,000
|
)
|
(350
|
)
|
(209,650
|
)
|
-
|
-
|
-
|
(210,000
|
)
|
|||||||||||||||
Common
stock issued pursuant
|
||||||||||||||||||||||||||||
to
subscription at $0.50 per
|
||||||||||||||||||||||||||||
share
in December 2005
|
-
|
-
|
40,000
|
40
|
19,960
|
(20,000
|
)
|
-
|
-
|
-
|
||||||||||||||||||
Common
Stock issued to investors
|
||||||||||||||||||||||||||||
pursuant
to registration rights
|
||||||||||||||||||||||||||||
agreement
at $0.51 per share in
|
||||||||||||||||||||||||||||
December
2005
|
-
|
-
|
505,854
|
506
|
257,480
|
-
|
-
|
-
|
257,986
|
|||||||||||||||||||
Common
Stock returned in
|
||||||||||||||||||||||||||||
January
2006, previously issued
|
||||||||||||||||||||||||||||
for
services rendered at $0.60
|
||||||||||||||||||||||||||||
per
share
|
-
|
-
|
(250,000
|
)
|
(250
|
)
|
(149,750
|
)
|
-
|
-
|
-
|
(150,000
|
)
|
|||||||||||||||
Common
Stock issued to investors
|
||||||||||||||||||||||||||||
pursuant
to registration rights
|
||||||||||||||||||||||||||||
agreement
at $0.32 per share
|
||||||||||||||||||||||||||||
in
January 2006
|
-
|
-
|
806,212
|
806
|
257,182
|
-
|
-
|
-
|
257,988
|
|||||||||||||||||||
Common
Stock issued to investors
|
||||||||||||||||||||||||||||
pursuant
to registration rights
|
||||||||||||||||||||||||||||
agreement
at $0.20 per share
|
||||||||||||||||||||||||||||
in
January 2006
|
-
|
-
|
1,289,927
|
1,290
|
256,695
|
-
|
-
|
-
|
257,985
|
|||||||||||||||||||
Fair
value of 200,000 warrants issued
|
||||||||||||||||||||||||||||
to
consultants for services at $0.22
|
||||||||||||||||||||||||||||
per
warrant in January 2006
|
-
|
-
|
-
|
-
|
43,098
|
-
|
-
|
-
|
43,098
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.17 per share in February 2006
|
-
|
-
|
160,000
|
160
|
27,040
|
-
|
-
|
-
|
27,200
|
|||||||||||||||||||
Common
Stock issued in
|
||||||||||||||||||||||||||||
exchange
for consulting services
|
||||||||||||||||||||||||||||
at
$0.16 per share in February 2006
|
-
|
-
|
3,800,000
|
3,800
|
604,200
|
-
|
-
|
-
|
608,000
|
|||||||||||||||||||
Common
Stock returned in
|
||||||||||||||||||||||||||||
March
2006, previously issued
|
||||||||||||||||||||||||||||
for
services rendered at $0.80
|
||||||||||||||||||||||||||||
per
share
|
-
|
-
|
(150,000
|
)
|
(150
|
)
|
(119,850
|
)
|
-
|
-
|
-
|
(120,000
|
)
|
|||||||||||||||
Previously
issued warrants reclassed
|
||||||||||||||||||||||||||||
to
warrant liability
|
-
|
-
|
-
|
-
|
(1,584,614
|
)
|
-
|
-
|
-
|
(1,584,614
|
)
|
|||||||||||||||||
Common
Stock issued in exchange
|
||||||||||||||||||||||||||||
for
consulting services at $0.20 per
|
||||||||||||||||||||||||||||
share
in July 2006
|
-
|
-
|
2,400,000
|
2,400
|
477,600
|
-
|
-
|
-
|
480,000
|
|||||||||||||||||||
Fair
value of stock options granted
|
||||||||||||||||||||||||||||
to
employees in exchange for
|
||||||||||||||||||||||||||||
services
rendered in September 2006
|
-
|
-
|
-
|
-
|
153,000
|
-
|
-
|
-
|
153,000
|
|||||||||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(2,410,237
|
)
|
(2,410,237
|
)
|
|||||||||||||||||
Balance
as of September 30, 2006
|
60,000
|
$
|
6
|
$
|
120,982,385
|
$
|
120,982
|
$
|
82,627,606
|
$
|
-
|
$
|
-
|
$
|
(92,334,791
|
)
|
$
|
(9,586,197
|
)
|
|||||||||
APPLIED
DNA SCIENCES, INC
|
||||||||||||||||||||||||||||
(A
development stage company)
|
||||||||||||||||||||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF STOCKHOLDER'S EQUITY,
(DEFICIENCY)
|
||||||||||||||||||||||||||||
FOR
THE PERIOD SEPTEMBER 16, 2002 (DATE OF INCEPTION) THROUGH
JUNE 30,
2007
(unaudited)
|
||||||||||||||||||||||||||||
Deficit
|
||||||||||||||||||||||||||||
Additional
|
Accumulated
|
|||||||||||||||||||||||||||
Preferred
|
Common
|
Paid
in
|
Common
|
Stock
|
During
|
|||||||||||||||||||||||
Preferred
|
Shares
|
Common
|
Stock
|
Capital
|
Stock
|
Subscription
|
Development
|
|||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Amount
|
Subscribed
|
Receivable
|
Stage
|
Total
|
||||||||||||||||||||
|
Common
stock issued in Dec 2006
|
||||||||||||||||||||||||||||
in
settlement of related party debt
|
||||||||||||||||||||||||||||
at
$2.28 per share
|
-
|
-
|
180,000
|
180
|
410,249
|
-
|
-
|
-
|
410,429
|
|||||||||||||||||||
Common
stock issued in May 2007
|
||||||||||||||||||||||||||||
in
settlement of convertible
|
||||||||||||||||||||||||||||
debenture
at $0.11per share
|
-
|
-
|
9,645,752
|
9,646
|
1,090,354
|
-
|
-
|
-
|
1,100,000
|
|||||||||||||||||||
Common
stock issued in June 2007
|
||||||||||||||||||||||||||||
in
settlement of convertible
|
||||||||||||||||||||||||||||
debenture
at $0.11per share
|
-
|
-
|
29,691,412
|
29,691
|
3,215,309
|
-
|
-
|
-
|
3,245,000
|
|||||||||||||||||||
Beneficial
conversion feature
|
||||||||||||||||||||||||||||
relating
to convertible debenture
|
-
|
-
|
-
|
-
|
76,788
|
-
|
-
|
-
|
76,788
|
|||||||||||||||||||
Net
loss
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
(8,233,506
|
)
|
(8,233,506
|
)
|
|||||||||||||||||
Balance
as of June 30, 2007
|
60,000
|
$
|
6
|
160,499,549
|
$
|
160,499
|
$
|
87,420,306
|
$
|
-
|
$
|
-
|
$
|
(100,568,297
|
)
|
$
|
(12,987,486
|
)
|
||||||||||
See
accompanying notes to consolidated financial statements
|
APPLIED
DNA SCIENCES, INC
|
||||||||||
(A
DEVELOPMENT STAGE COMPANY)
|
||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF CASH FLOWS
|
||||||||||
(unaudited)
|
||||||||||
For
the Period
|
||||||||||
September
16, 2002
|
||||||||||
(Date
of Inception)
|
||||||||||
For
the nine months ended June 30,
|
through
|
|||||||||
2007
|
2006
|
June
30, 2007
|
||||||||
Cash
flows from operating activities:
|
RESTATED
|
|||||||||
Net
income (loss)
|
$
|
(8,233,506
|
)
|
$
|
5,606,849
|
$
|
(100,568,297
|
)
|
||
Adjustments
to reconcile net loss to net used in operating activities:
|
||||||||||
Depreciation
and amortization
|
324,594
|
1,021,199
|
2,054,320
|
|||||||
Organization
expenses
|
-
|
-
|
88,500
|
|||||||
Impairment
of intangible assets
|
-
|
-
|
5,655,011
|
|||||||
Preferred
shares issued in exchange for services
|
-
|
-
|
1,500,000
|
|||||||
Options
and warrants issued in exchange for services rendered
|
-
|
43,100
|
11,001,255
|
|||||||
Income
attributable to repricing of warrants and debt derivatives
|
(142,131
|
)
|
(14,250,621
|
)
|
(33,687,959
|
)
|
||||
Financing
costs attributable to issuance of warrants
|
-
|
2,271,000
|
25,419,214
|
|||||||
Amortization
of beneficial conversion feature-convertible notes
|
10,093
|
-
|
10,471,093
|
|||||||
Amortization
of capitalized financing costs
|
1,005,975
|
247,238
|
1,641,988
|
|||||||
Amortization
of debt discount attributable to convertible debentures
|
1,580,519
|
276,090
|
2,312,009
|
|||||||
Debt
in exchange for common stock at fair market price
|
-
|
-
|
1,365,000
|
|||||||
Common
stock issued in exchange for services rendered
|
-
|
710,200
|
31,964,573
|
|||||||
Common
stock exchanged for intellectual property in connection with costs
of
acquiring
intangible assets
|
-
|
-
|
14,689,100
|
|||||||
Common
stock issued in connection with penalties pursuant to
registration
|
-
|
773,958
|
1,550,487
|
|||||||
Common
stock canceled-previously issued for services rendered
|
-
|
(480,000
|
)
|
(1,343,845
|
)
|
|||||
Change
in assets and liabilities:
|
||||||||||
Decrease
(increase) in accounts receivable
|
9,631
|
(18,900
|
)
|
-
|
||||||
Decrease
(increase) in prepaid expenses and deposits
|
(32,208
|
)
|
(145,849
|
)
|
(153,137
|
)
|
||||
Decrease
(increase) in other assets
|
8,419
|
5,940
|
(13,450
|
)
|
||||||
Increase
in due related parties
|
-
|
(52,662
|
)
|
40,753
|
||||||
Increase
(decrease) in accounts payable and accrued liabilities
|
3,811,641
|
1,685,792
|
8,737,251
|
|||||||
Net
cash used in operating activities
|
(1,656,973
|
)
|
(2,306,666
|
)
|
(17,276,134
|
)
|
||||
Cash
flows from investing activities:
|
||||||||||
Payments
for patent filing
|
-
|
-
|
(25,698
|
)
|
||||||
Acquisition
(disposal) of property and equipment, net
|
(11,039
|
)
|
(35,851
|
)
|
(188,360
|
)
|
||||
Net
cash provided by (used in) investing activities
|
(11,039
|
)
|
(35,851
|
)
|
(214,058
|
)
|
||||
Cash
flows from financing activities:
|
||||||||||
Proceeds
from sale of common stock, net of cost
|
-
|
-
|
432,000
|
|||||||
Proceeds
from issuance of convertible notes, net of costs
|
477,500
|
4,242,500
|
13,924,000
|
|||||||
Proceeds
from sale of options
|
-
|
-
|
343,750
|
|||||||
Repayment
of debt
|
-
|
-
|
(24,854
|
)
|
||||||
Proceeds
from loans
|
-
|
-
|
2,750,000
|
|||||||
Advances
from shareholders
|
-
|
-
|
100,088
|
|||||||
Net
cash provided by financing activities
|
477,500
|
4,242,500
|
17,524,984
|
|||||||
Net
increase in cash and cash equivalents
|
(1,190,512
|
)
|
1,899,983
|
34,792
|
||||||
Cash
and cash equivalents at beginning of period
|
1,225,304
|
31,190
|
-
|
|||||||
Cash
and cash equivalents at end of period
|
$
|
34,792
|
$
|
1,931,173
|
$
|
34,792
|
APPLIED
DNA SCIENCES, INC
|
||||||||||
(A
DEVELOPMENT STAGE COMPANY)
|
||||||||||
CONDENSED
CONSOLIDATED STATEMENT OF CASH FLOWS
|
||||||||||
(unaudited)
|
||||||||||
For
the Period
|
||||||||||
September
16, 2002
|
||||||||||
(Date
of Inception)
|
||||||||||
For
the nine months ended June 30,
|
through
|
|||||||||
2007
|
2006
|
June
30, 2007
|
||||||||
Supplemental
Disclosures of Cash Flow Information:
|
||||||||||
Cash
paid during period for interest
|
-
|
-
|
-
|
|||||||
Cash
paid during period for taxes
|
-
|
-
|
-
|
|||||||
Non-cash
transactions:
|
||||||||||
Common
stock issued for services
|
-
|
710,200
|
31,964,573
|
|||||||
Common
stock issued in exchange for intellectual property
|
-
|
-
|
||||||||
Common
stock issued in exchange for previously incurred debt
|
4,361,200
|
-
|
2,313,500
|
|||||||
Common
stock canceled-previously issued for services rendered
|
-
|
(480,000
|
)
|
(1,343,845
|
)
|
|||||
Common
stock issued for ESOP shares
|
-
|
-
|
||||||||
Common
stock penalty shares issued pursuant to Pending SB-2
registration
|
-
|
773,958
|
||||||||
Amortization
of beneficial conversion feature
|
-
|
-
|
10,471,093
|
|||||||
Preferred
shares in exchange for service at $25 per share in September
2004
|
-
|
-
|
1,500,000
|
|||||||
Fair
value of options and warrants issued to consultants for
services
|
-
|
43,100
|
11,001,255
|
|||||||
Acquisition:
|
||||||||||
Common
stock retained
|
-
|
-
|
1,015
|
|||||||
Assets
acquired
|
-
|
-
|
(135
|
)
|
||||||
Total
consideration paid
|
-
|
-
|
880
|
|||||||
Organizational
expenses-note issued in exchange for shares retired
|
88,500
|
|||||||||
Common
stock issued in exchange for note payable
|
88,500
|
|||||||||
See
the accompanying notes to the consolidated financial
statements
|
Computer
equipment
|
$
|
27,404
|
||
Lab
equipment
|
54,974
|
|||
Furniture
|
105,984
|
|||
Accumulated
depreciation
|
(67,497
|
)
|
||
Net
|
$
|
120,865
|
Three
Months Ended
June
30, 2007
|
Three
Months Ended
June
30, 2006
|
Nine
Months Ended
June
30, 2006
|
||||||||
Net
income used in computing basic net income per share
|
$
|
1,807,954
|
$
|
761,087
|
$
|
5,606,849
|
||||
Impact
of assumed assumptions:
|
||||||||||
Fair
value of warrants relating to convertible debt charged to interest
expense
|
-
|
-
|
1,758,900
|
|||||||
Impact
of equity classified as liability:
|
||||||||||
Gain
on warrant liability marked to fair value
|
(4,431,421
|
)
|
(3,493,961
|
)
|
(14,250,621
|
)
|
||||
Net
loss in computing diluted net loss per share:
|
$
|
(2,623,467
|
)
|
$
|
(2,732,874
|
)
|
$
|
(6,884,872
|
)
|
Developed
core technologies
|
$
|
2,260,900
|
|||
Developed
product technologies
|
7,170,000
|
||||
Total
amortizable intangible assets
|
9,430,900
|
||||
Transaction
costs
|
14,869,100
|
||||
Total
purchase price
|
$
|
24,120,000
|
Trade
secrets and developed technologies (Weighted average life of 7
years)
|
$
|
9,430,900
|
||
Patents
(Weighted average life of 5 years)
|
34,257
|
|||
Total
Amortized identifiable intangible assets-Gross carrying value:
|
$
|
9,465,157
|
||
Less:
|
||||
Accumulated
Amortization
|
(1,980,664
|
)
|
||
Impairment
|
(5,655,011
|
)
|
||
Net:
|
$
|
1,829,482
|
||
Residual
value:
|
$
|
0
|
2007
|
$
|
277,982
|
|||
2008
|
370,642
|
||||
2009
|
365,504
|
||||
2010
|
363,791
|
||||
2011
and thereafter
|
451,563
|
||||
Total
|
$
|
1,829,482
|
10%
Secured Convertible Notes Payable dated March 8, 2006, net of unamortized
debt discount of $107,710 (see below)
|
$
|
1,392,290
|
|||
10%
Secured Convertible Notes Payable, related party, dated April 23,
2007,
net of unamortized debt discount of $44,081 (see below)
|
55,919
|
||||
10%
Secured Convertible Notes Payable dated June 27, 2007 (See
below)
|
100,000
|
||||
10%
Secured Convertible Notes Payable dated June 27, 2007 (See
below)
|
50,000
|
||||
10%
Secured Convertible Notes Payable, related party, dated June 30,
2007, net
of unamortized debt discount of $102,354 (see below)
|
147,646
|
||||
1,745,855
|
|||||
Less:
current portion
|
(1,745,855
|
)
|
|||
$
|
-
|
· |
105,464
warrants entitling the holder to purchase 105,464 shares of the Company’s
common stock at the price of $0.10 per share. These warrants were
issued in July, 2004 and lapse if unexercised by July, 2009.
|
· |
1,602,500
warrants entitling the holder to purchase 1,602,500 shares of the
Company’s common stock at the price of $0.60 per share. These
warrants were issued in October, 2003 and lapse if unexercised by
October,
2008.
|
Exercise
Prices
|
Number
Outstanding
|
Warrants
Outstanding Remaining Contractual Life (Years)
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Exercisable
|
Exercisable
Weighted
Average
Exercise
Price
|
|||||||||||
$0.09
|
18,900,000
|
4.17
|
$
|
0.09
|
18,900,000
|
$
|
0.09
|
|||||||||
$0.10
|
105,464
|
2.01
|
$
|
0.10
|
105,464
|
$
|
0.10
|
|||||||||
$0.20
|
5,000
|
1.64
|
$
|
0.20
|
5,000
|
$
|
0.20
|
|||||||||
$0.50
|
17,450,000
|
3.02
|
$
|
0.50
|
16,450,000
|
$
|
0.50
|
|||||||||
$0.55
|
9,000,000
|
1.72
|
$
|
0.55
|
9,000,000
|
$
|
0.55
|
|||||||||
$0.60
|
8,847,000
|
2.63
|
$
|
0.60
|
8,847,000
|
$
|
0.60
|
|||||||||
$0.70
|
950,000
|
0.84
|
$
|
0.70
|
950,000
|
$
|
0.70
|
|||||||||
$0.75
|
17,727,000
|
3.00
|
$
|
0.75
|
17,727,000
|
$
|
0.75
|
|||||||||
72,984,464
|
71,984,464
|
Number
of
Shares
|
Weighted
Average
Price
Per
Share
|
||||||
Balance,
September 30, 2004
|
4,870,253
|
$
|
0.63
|
||||
Granted
|
32,873,000
|
0.71
|
|||||
Exercised
|
(142,500
|
)
|
.0.34
|
||||
Canceled
or expired
|
(731,289
|
)
|
0.65
|
||||
Balance,
September 30, 2005
|
36,869,464
|
0.67
|
|||||
Granted
|
35,500,000
|
0.29
|
|||||
Exercised
|
-
|
-
|
|||||
Canceled
or expired
|
-
|
-
|
|||||
Outstanding
at September 30, 2006
|
72,369,464
|
0.48
|
|||||
Granted
|
1,000,000
|
0.50
|
|||||
Exercised
|
-
|
-
|
|||||
Canceled
or expired
|
(385,000
|
)
|
(0.71
|
)
|
|||
Balance,
June 30, 2007
|
72,984,464
|
$
|
0.48
|
Options
Outstanding
|
Options
Exercisable
|
||||||||||||||||
Exercise
Prices
|
Number
Outstanding
|
Weighted
Average
Remaining
Contractual
Life
(Years)
|
Weighted
Average
Exercise
Price
|
Number
Exercisable
|
Weighted
Average
Exercise
Price
|
||||||||||||
$ |
0.68
|
3,660,000
|
4.25
|
$
|
0.68
|
3,660,000
|
$
|
0.68
|
|||||||||
0.09
|
2,000,000
|
4.41
|
0.09
|
2,000,000
|
0.09
|
||||||||||||
5,660,000
|
5,660,000
|
0.47
|
Number
of
Shares
|
Weighted
Average
Exercise Price
Per Share
|
||||||
Outstanding
at October 1, 2005
|
3,660,000
|
$
|
0.68
|
||||
Granted
|
2,000,000
|
0.09
|
|||||
Exercised
|
-
|
-
|
|||||
Cancelled
or expired
|
-
|
-
|
|||||
Outstanding
at September 30, 2006
|
5,660,000
|
$
|
0.47
|
||||
Granted
|
-
|
-
|
|||||
Exercised
|
-
|
-
|
|||||
Canceled
or expired
|
-
|
-
|
|||||
Outstanding
at June 30, 2007
|
5,660,000
|
$
|
0.47
|
As Previously
|
||||||||||||||||
Reported
|
Adjustment
|
Reference
|
As Restated
|
|||||||||||||
Cash
|
$
|
1,931,173
|
$
|
1,931,173
|
||||||||||||
Accounts
receivable, net
|
$
|
18,900
|
$
|
18,900
|
||||||||||||
Advances
and other receivables
|
$
|
11,611
|
$
|
11,611
|
||||||||||||
Prepaid
expenses
|
$
|
146,667
|
$
|
146,667
|
||||||||||||
Total
current assets
|
$
|
2,108,351
|
$
|
2,108,351
|
||||||||||||
Property,
plant and equipment, net
|
$
|
38,286
|
$
|
38,286
|
||||||||||||
Deposits
|
$
|
8,322
|
$
|
8,322
|
||||||||||||
Capitalized
finance costs
|
$
|
1,437,862
|
$
|
1,437,862
|
||||||||||||
Patents,
net
|
$
|
17,376
|
$
|
17,376
|
||||||||||||
Intellectual
property, net
|
$
|
8,083,629
|
$
|
8,083,629
|
||||||||||||
Total
assets
|
$
|
11,693,826
|
$
|
11,693,826
|
||||||||||||
Accounts
payable and accrued liabilities
|
$
|
4,680,849
|
$
|
4,680,849
|
||||||||||||
Notes
payable, related party
|
$
|
410,429
|
$
|
410,429
|
||||||||||||
Total
current liabilities
|
$
|
5,091,278
|
$
|
5,091,278
|
As
Previously
Reported
|
Adjustment
|
Reference
|
As Restated
|
Convertible
notes payable, net
|
$
|
3,306,371
|
$
|
$
|
3,306,371
|
||||||||
Debt
derivative and warrant liability
|
$
|
5,698,286
|
$
|
$
|
5,698,286
|
||||||||
Total
liabilities
|
$
|
14,095,935
|
$
|
$
|
14,095,935
|
||||||||
Preferred
stock
|
$
|
6
|
$
|
$
|
6
|
||||||||
Common
stock
|
$
|
118,582
|
$
|
$
|
118,582
|
||||||||
Common
stock subscription
|
$
|
(200,000
|
)
|
$
|
$
|
(200,000
|
)
|
||||||
Additional
paid in capital
|
$
|
81,860,606
|
$
|
136,400
|
a
|
$
|
81,997,006
|
||||||
Accumulated
deficit
|
$
|
(84,181,303
|
)
|
$
|
(136,400
|
)
|
a
|
$
|
(84,317,703
|
)
|
|||
Total
deficiency in stockholders’ equity
|
$
|
(2,402,109
|
)
|
$
|
(2,402,109
|
)
|
|||||||
Total
liabilities and Deficiency in Stockholders’ equity
|
$
|
11,693,826
|
$
|
11,693,826
|
|||||||||
As
Previously
Reported
|
Adjustment
|
Reference
|
As Restated
|
||||||||||
Sales
|
$
|
18,900
|
$
|
18,900
|
|||||||||
Cost
of sales
|
$
|
15,639
|
$
|
15,639
|
|||||||||
Gross
margin
|
$
|
3,261
|
$
|
3,261
|
|||||||||
Selling,
general & administrative
|
$
|
1,190,967
|
$
|
390,000
|
|
b
|
$
|
1,580,967
|
|||||
Research
and development
|
$
|
-
|
$
|
$
|
-
|
||||||||
Depreciation
and amortization
|
$
|
336,824
|
$
|
336,824
|
|||||||||
Total
operating expenses
|
$
|
1,527,791
|
$
|
390,000
|
|
b
|
$
|
1,917,791
|
|||||
Net
loss from operations
|
$
|
(1,524,530
|
)
|
$
|
(390,000
|
)
|
b
|
$
|
(1,914,530
|
)
|
|||
Net
gain (loss) in fair value of debt derivative
and
warrant liability
|
$
|
2,337,263
|
$
|
1,156,698
|
c
|
$
|
3,493,961
|
||||||
Other
income (expense)
|
$
|
8,483
|
$
|
8,483
|
|||||||||
Interest
income (expense)
|
$
|
(826,827
|
)
|
$
|
(826,827
|
)
|
|||||||
Net
income (loss)
|
$
|
(5,611
|
)
|
$
|
766,698
|
b,c
|
$
|
761,087
|
|||||
Net
income (loss) per share-basic
|
$
|
(0.00
|
)
|
$
|
0.01
|
$
|
0.01
|
||||||
Net
income (loss) per share-fully diluted
|
NA
|
$
|
0.01
|
$
|
0.01
|
As
Previously
Reported
|
Adjustment
|
Reference
|
As Restated
|
|||||||||||
Sales
|
$
|
18,900
|
$
|
18,900
|
||||||||||
Cost
of sales
|
$
|
15,639
|
$
|
15,639
|
||||||||||
Gross
margin
|
$
|
3,261
|
$
|
3,261
|
||||||||||
Selling,
general & administrative
|
$
|
4,955,055
|
$
|
(563,750
|
)
|
|
d
|
$
|
4,391,305
|
|||||
Research
and development
|
$
|
75,276
|
$
|
$
|
75,276
|
|||||||||
Depreciation
and amortization
|
$
|
1,021,199
|
$
|
1,021,199
|
||||||||||
Total
operating expenses
|
$
|
6,051,530
|
$
|
(563,750
|
)
|
d
|
$
|
5,487,780
|
||||||
Net
loss from operations
|
$
|
(6,048,269
|
)
|
$
|
563,750
|
)
|
d
|
$
|
(5,484,519
|
)
|
||||
Net
gain (loss) in fair value of debt derivative
and
warrant liability
|
$
|
18,606,563
|
$
|
(4,355,942
|
)
|
e
|
$
|
14,250,621
|
||||||
Other
income (expense)
|
$
|
17.976
|
$
|
17,976
|
||||||||||
Interest
income (expense)
|
$
|
(9,117,785
|
)
|
$
|
5,940,556
|
f
|
$
|
(3,177,229
|
)
|
|||||
Net
income (loss)
|
$
|
3,458,485
|
$
|
2,148,364
|
d,e,f
|
$
|
5,606,849
|
|||||||
Net
income (loss) per share-basic
|
$
|
0.03
|
0.02
|
$
|
0.05
|
|||||||||
Net
income (loss) per share-fully diluted
|
0.02
|
0.01
|
$
|
0.03
|
As
Previously
Reported
|
Adjustment
|
Reference
|
As Restated
|
||||||||||
Sales
|
$
|
18,900
|
$
|
$
|
18,900
|
||||||||
Cost
of sales
|
$
|
15,639
|
$
|
$
|
15,639
|
||||||||
Gross
margin
|
$
|
3,261
|
$
|
$
|
3,261
|
||||||||
Selling,
general & administrative
|
$
|
70,072,368
|
$
|
5,838,514
|
|
g
|
$
|
75,910,882
|
|||||
Research
and development
|
$
|
968,711
|
$
|
$
|
968,711
|
||||||||
Depreciation
and amortization
|
$
|
1,380,626
|
$
|
$
|
1,380,626
|
||||||||
Total
operating expenses
|
$
|
72,421,705
|
$
|
5,838,514
|
|
g
|
$
|
78,260,219
|
|||||
Net
loss from operations
|
$
|
(72,418,444
|
)
|
$
|
(5,838,514
|
)
|
|
g
|
$
|
(78,256,958
|
)
|
||
Net
gain (loss) in fair value of debt derivative
and
warrant liability
|
$
|
35,307,553
|
$
|
(4,355,942
|
)
|
e
|
$
|
30,951,611
|
|||||
Other
income (expense)
|
$
|
49,318
|
49,318
|
||||||||||
Interest
income (expense)
|
$
|
(47,119,730
|
)
|
$
|
10,058,055
|
h
|
$
|
(37,061,675
|
)
|
||||
Net
income (loss)
|
$
|
(84,181,303
|
)
|
$
|
(136,401
|
)
|
g,e,h
|
$
|
(84,317,703
|
)
|
As
Previously
Reported
|
Adjustment
|
Reference
|
As Restated
|
||||||||||
Cash
flows from operating activities:
|
|||||||||||||
Net
income (loss)
|
$
|
3,458,485
|
$
|
2,148,364
|
a
|
$
|
5,606,849
|
||||||
Adjustments
to reconcile to net used in operating activities
|
|||||||||||||
Depreciation
and amortization
|
$
|
1,021,199
|
$
|
1,021,199
|
|||||||||
Organization
expenses
|
$
|
$ |
$
|
||||||||||
Preferred
shares issued in exchange for services
|
$
|
-
|
$
|
$
|
-
|
||||||||
Warrants
issued to consultants
|
$
|
606,850
|
$
|
(563,750
|
)
|
d
|
$
|
43,100
|
|||||
Income
attributable to repricing of warrants and debt derivatives
|
$
|
(10,118,917
|
)
|
$
|
(4,131,704
|
)
|
i
|
$
|
(14,250,621
|
)
|
|||
Financing
costs attributable to issuance of warrants
|
$
|
2,271,000
|
j
|
$
|
2,271,000
|
||||||||
Amortization
of beneficial conversion feature -convertible notes
|
$
|
-
|
$
|
$
|
-
|
||||||||
Amortization
of capitalized finance costs
|
$
|
247,238
|
$
|
$
|
247,238
|
||||||||
Amortization
of debt discount attributable to convertible debenture
|
$
|
-
|
$
|
276,090
|
k
|
$
|
276,090
|
||||||
Fair
value of common stock issued to related party in excess
of
debt
|
$
|
-
|
$
|
$
|
-
|
||||||||
Common
stock issued in exchange for services
|
$
|
710,200
|
$
|
$
|
710,200
|
||||||||
Common
stock issued in exchange for intellectual property
|
$
|
-
|
$
|
$
|
-
|
||||||||
Common
stock issued as penalty in connection with financing
|
$
|
773,958
|
$
|
$
|
773,958
|
||||||||
Common
stock canceled-previously issued for services rendered
|
$
|
(480,000
|
)
|
$
|
$
|
(480,000
|
)
|
||||||
Change
in assets and liabilities:
|
|||||||||||||
Increase
in accounts receivable
|
$
|
(18,900
|
)
|
$
|
$
|
(18,900
|
)
|
As
Previously
Reported
|
Adjustment
|
Reference
|
As Restated
|
Increase
in prepaid expenses and deposits
|
$
|
(145,849
|
)
|
$
|
$
|
(145,849
|
)
|
||||||
Decrease
in other assets
|
$
|
5,940
|
$
|
$
|
5,940
|
||||||||
Decease
in due related parties
|
$
|
(52,662
|
)
|
$
|
(52,662
|
)
|
|||||||
Increase
(decrease) in accounts payable and accrued liabilities
|
$
|
1,685,792
|
$
|
1,685,792
|
|||||||||
Net
cash used in operating activities
|
$
|
(2,306,666
|
)
|
$
|
(2,306,666
|
)
|
|||||||
Cash
flows from investing activities:
|
$
|
||||||||||||
Payments
for patent filing
|
$
|
-
|
$
|
||||||||||
Capital
expenditures
|
$
|
(35,851
|
)
|
$
|
(35,851
|
)
|
|||||||
Net
cash used in investing activities
|
$
|
(35,851
|
)
|
$
|
(35,851
|
)
|
|||||||
Cash
flows from financing activities
|
$
|
||||||||||||
Proceeds
from sales of common stock, net
|
$
|
-
|
$
|
||||||||||
Proceeds
form issuance of convertible notes
|
$
|
4,242,500
|
$
|
4,242,500
|
|||||||||
Proceeds
from exercise of options and warrants
|
$
|
-
|
$
|
-
|
|||||||||
Payment
of debt
|
$
|
-
|
$
|
-
|
|||||||||
Proceeds
from loans
|
$
|
-
|
$
|
-
|
|||||||||
Advances
from shareholders
|
$
|
-
|
$
|
-
|
|||||||||
Net
cash provided by financing activities
|
$
|
4,242,500
|
$
|
4,242,500
|
|||||||||
Net
increase in cash and cash equivalents
|
$
|
1,899,983
|
$
|
1,899,983
|
|||||||||
Cash
and cash equivalents at beginning of period
|
$
|
31,190
|
$
|
31,190
|
|||||||||
Cash
and cash equivalents at end of period
|
$
|
1,931,173
|
$
|
1,931,173
|
As
Previously
Reported
|
Adjustment
|
Reference
|
As Restated
|
||||||||||
Cash
flows from operating activities:
|
|||||||||||||
Net
income (loss)
|
$
|
(84,181,303
|
)
|
$
|
(136,400
|
)
|
|
g,e,f
|
$
|
(84,317,703
|
)
|
||
Adjustments
to reconcile to net used in operating activities
|
|||||||||||||
Depreciation
and amortization
|
$
|
1,374,467
|
$
|
(5,756
|
)
|
|
l
|
$
|
1,368,711
|
||||
Organization
expenses
|
$
|
88,500
|
$
|
$
|
88,500
|
||||||||
Preferred
shares issued in exchange for services
|
$
|
1,500,000
|
$
|
$
|
1,500,000
|
||||||||
Warrants
issued to consultants
|
$
|
3,583,016
|
$
|
5,838,514
|
g
|
$
|
9,421,530
|
||||||
Income
attributable to repricing of warrants and debt derivatives
|
$
|
(26,819,908
|
)
|
$
|
(4,131,703
|
)
|
i
|
$
|
(30,951,611
|
)
|
|||
Financing
costs attributable to issuance of warrants
|
$
|
27,265,174
|
$
|
(1,846,500
|
)
|
m
|
$
|
25,418,674
|
|||||
Amortization
of beneficial conversion feature -convertible notes
|
$
|
10,461,000
|
$
|
$
|
10,461,000
|
||||||||
Amortization
of capitalized finance costs
|
$
|
247,238
|
$
|
$
|
247,238
|
||||||||
Amortization
of debt discount attributable to convertible debenture
|
$
|
-
|
$
|
276,090
|
k
|
$
|
276,090
|
||||||
Fair
value of common stock issued to related party in excess
of
debt
|
$
|
1,365,000
|
$
|
$
|
1,365,000
|
||||||||
Common
stock issued in exchange for services
|
$
|
31,284,573
|
$
|
$
|
31,284,573
|
||||||||
Common
stock issued in exchange for intellectual property
|
$
|
14,689,100
|
$
|
$
|
14,689,100
|
||||||||
Common
stock issued as penalty in connection with financing
|
$
|
1,550,487
|
$
|
$
|
1,550,487
|
||||||||
Common
stock canceled-previously issued for services rendered
|
$
|
(1,343,845
|
)
|
$
|
$
|
(1,343,845
|
)
|
||||||
Change
in assets and liabilities:
|
$
|
$
|
|||||||||||
Increase
in accounts receivable
|
$
|
(18,900
|
)
|
$
|
$
|
(18,900
|
)
|
As
Previously
Reported
|
Adjustment
|
Reference
|
As Restated
|
Increase
in prepaid expenses and deposits
|
$
|
(163,472
|
)
|
$ |
$
|
(163,472
|
)
|
||||||
Decrease
in other assets
|
$
|
(3,128
|
)
|
$
|
$
|
(3,128
|
)
|
||||||
Decease
in due related parties
|
$
|
-
|
$
|
$
|
-
|
||||||||
Increase
(decrease) in accounts payable and accrued liabilities
|
$
|
4,079,990
|
$
|
5,755
|
l
|
$
|
4,085,745
|
||||||
Net
cash used in operating activities
|
$
|
(15,042,011
|
)
|
$
|
$
|
(15,042,011
|
)
|
||||||
Cash
flows from investing activities:
|
|
||||||||||||
Payments
for patent filing
|
$
|
(25,698
|
)
|
$
|
$
|
(25,698
|
)
|
||||||
Capital
expenditures
|
$
|
(48,602
|
)
|
$
|
$
|
(48,602
|
)
|
||||||
Net
cash used in investing activities
|
$
|
(74,300
|
)
|
$
|
$
|
(74,300
|
)
|
||||||
Cash
flows from financing activities
|
|||||||||||||
Proceeds
from sales of common stock, net
|
$
|
432,000
|
$
|
$
|
432,000
|
||||||||
Proceeds
form issuance of convertible notes
|
$
|
13,446,500
|
$
|
$
|
13,446,500
|
||||||||
Proceeds
from exercise of options and warrants
|
$
|
343,750
|
$
|
$
|
343,750
|
||||||||
Payment
of debt
|
$
|
(24,854
|
)
|
$
|
$
|
(24,854
|
)
|
||||||
Proceeds
from loans
|
$
|
2,750,000
|
$
|
$
|
2,750,000
|
||||||||
Advances
from shareholders
|
$
|
100,088
|
$
|
$
|
100,088
|
||||||||
Net
cash provided by financing activities
|
$
|
17,047,484
|
$
|
$
|
17,047,484
|
||||||||
Net
increase in cash and cash equivalents
|
$
|
1,931,173
|
$
|
$
|
1,931,173
|
||||||||
Cash
and cash equivalents at beginning of period
|
$
|
-
|
$
|
$
|
-
|
||||||||
Cash
and cash equivalents at end of period
|
$
|
1,931,173
|
$
|
$
|
1,931,173
|
a. |
Subsequent
to the filing of the Company’s June 30, 2006 quarterly report, the Company
identified and amended its September 30, 2005 financial statements.
The
Company reported in the initial June 30, 2006 quarterly filing
adjustments
relating to warrant valuations in the current year, but upon
subsequent
review, realized these adjustments related to the prior year.
The
following table describes the effect on Additional Paid in
Capital and
Accumulated Deficit within the balance sheet and change in
operations:
|
Prior
year
|
||||||||||||||||
Unaffected
|
Additional
|
Accumulated
|
Total
|
Activity
charged
|
||||||||||||
SE
items
|
Paid
in Capital
|
Deficit
|
Deficiency
|
to
operations
|
||||||||||||
Balance,
October 1, 2004-As previously reported
and
restated
|
$
|
11,989,533
|
$
|
6,118,993
|
$
|
(22,815,034
|
)
|
$
|
(4,706,508
|
)
|
||||||
Unchanged
activity reported as previously filed during year ended
September 30,
2005
|
(11,857,297
|
)
|
73,916,958
|
(64,824,755
|
)
|
(2,765,094
|
)
|
|||||||||
Balance
as previously filed, September 30, 2005
|
132,236
|
80,035,951
|
(87,639,789
|
)
|
(7,471,602
|
)
|
||||||||||
Activity
corrected with amended September 30, 2005 filing, but subsequent
to
previously filed June 30, 2006:
|
||||||||||||||||
Correction
of fair value of warrants issued for services rendered
in December
2004
|
-
|
(394,698
|
)
|
394,698
|
-
|
$
|
(394,698
|
)
|
||||||||
Fair
value of warrants issued to non employees and consultants
in December
2004
|
-
|
3,169,052
|
(3,169,052
|
)
|
-
|
3,169,052
|
||||||||||
Fair
value of warrants issued to non employees in February 2005
|
-
|
72,017
|
(72,017
|
)
|
-
|
72,017
|
||||||||||
Correction
of warrants issued to consultants and employees in June
2005
|
-
|
(849,047
|
)
|
849,047
|
-
|
(849,047
|
)
|
|||||||||
Adjustment
for cancellation of previously issued warrants during year
ended September
30, 2005
|
-
|
287,440
|
(287,440
|
)
|
-
|
287,440
|
||||||||||
Balance
per amended September 30, 2005
|
132,236
|
82,320,715
|
(89,924,553
|
)
|
(7,471,602
|
)
|
2,284,764
|
|||||||||
Unchanged
activity reported as previously filed during nine months
ended June 30,
2006
|
(213,648
|
)
|
(460,109
|
)
|
5,743,249
|
5,069,492
|
||||||||||
Previously
filed June 30, 2006
|
(81,412
|
)
|
81,860,606
|
$
|
(84,181,304
|
)
|
$
|
(2,402,110
|
)
|
|||||||
Correction
in warrant valuation
|
136,400
|
(136,400
|
)
|
-
|
(136,400
|
)
|
||||||||||
Amended
June 30, 2006:
|
$
|
(81,412
|
)
|
$
|
81,997,006
|
$
|
(84,317,704
|
)
|
$
|
(2,402,110
|
)
|
|||||
Net
change to operations:
|
$
|
2,148,364
|
b. |
For
the three months ended June 2006, the Company capitalized
(and credited
operations) finance costs paid and charged to operations
in the previous
quarter. The correction is to reflect within the proper accounting
period
the incurred capitalized financing costs. Net effect for
the three months
ended June 30, 2006: $390,000 reduction in operating expenses.
Net effect
for the nine months ended June 30, 2006:
None
|
c. |
Subsequent
to the filing of the Company’s June 30, 2006 quarterly report, the Company
amended its March 31, 2006 filing to correct warrant
valuations. The
following table reconciles the amended Net gain
in fair value of debt
derivative and warrant liability:
|
Debt
derivative and warrant liability balance as reported
in March 2006 amended
QSB:
|
$
|
7,631,128
|
||
Debt
derivative and warrant liability balance as reported
in June 2006 amended
QSB (unchanged)
|
5,698,286
|
|||
Net
change
|
1,932,842
|
|||
Effect
on gain created by initial warrant valuations
relating to warrants issued
in conjunction with convertible debt issued in
June 2006
(unchanged)
|
1,561,119
|
|||
Amended
Net gain in fair value of debt derivative and
warrant
liability:
|
$
|
3,493,961
|
d. |
The
Company originally charged Selling, General and
Administration for
warrants issued relating to financing activities.
The correct charge is to
interest expense.
|
e. |
The
Company change in net gain in fair value of debt
derivative and warrant
liability is comprised of the following:
|
The
Company reported change in debt derivative and
warrant valuation as an
interest charge. Reclassification from interest
expense
|
$
|
5,940,556
|
||
Correction
noted in (a) above
|
(2,148,364
|
)
|
||
Correction
noted in (d) above
|
563,750
|
|||
Net
change in Net gain in fair value of debt derivative
and warrant
liability:
|
$
|
4,355,942
|
f. |
Reclassification
from interest expense to gain on change in fair
value of debt derivative
and warrant liability. The Company originally recorded
in error the change
in debt derivative and warrant valuations as a
credit to interest expense.
This correction is a reclassification to the proper
account. Net effect
was $5,940,556.
|
g. |
The
Company amended in prior filings the original recorded
non financing
related warrants which were recorded as a charge
to interest expense. The
corrected proper treatment is a charge to selling
general and
administration expense.
|
h. |
The
Inception to date change in interest
expense is comprised of the
following:
|
Reclassification
from interest expense as described
in (f) above:
|
$
|
5,940,556
|
|||
Reclassification
from selling, general and administration
expense as
described
in (g) above
|
$
|
5,838,514
|
|||
Correction
as noted in (a) above
|
(2,148,364
|
)
|
|||
Correction
as noted in (d) above
|
563,750
|
||||
Correction
in warrant valuation as noted in
(a) above
|
(136,400
|
)
|
|||
Net
change in inception to date reported
interest expense:
|
$
|
10,058,055
|
i. |
The
change in reported net gain in fair
value of debt derivative and warrant
liability is comprised of the
following:
|
Reclassification
with the cash flow statement initial
warrant valuations relating
to
financing (see j below)
|
$
|
2,271,000
|
|||
Correction
as noted in (a) above
|
2,148,364
|
||||
Correction
as noted in (d) above
|
(563,750
|
)
|
|||
Reclassification
of amortization of capitalized financing
costs (see k below)
|
276,090
|
||||
Net
change in reported fair value of
debt derivative and warrant
liability:
|
$
|
4,131,704
|
j. |
Effect
of recording the non cash financing
costs relating to issuance of warrants
of $2,271,000 (reclassified from net
change in fair value of debt and
derivative valuations)
|
k. |
Recording
the non cash amortization relating
to the financing costs described in
(j)
above. (Reclassified from net change
in fair value of debt and derivative
valuations)
|
l. |
Correction
of inception to date non cash depreciation
and amortization on the cash
flow statement.
|
m. |
Correct
the life to date non cash financing
costs attributable to warrants, net
of
amortization (k).
|
· |
discuss
our future expectations;
|
· |
contain
projections of our future results of operations or of our financial
condition; and
|
· |
state
other “forward-looking”
information.
|
· |
assure
manufacturers, suppliers, distributors, retailers and end-users that
their
products are authentic and can be forensically
authenticated;
|
· |
integrate
our SigNature DNA Markers with existing security solutions such as
barcodes, radio frequency identification (RFID) tags, holograms,
microchips and other securities measures;
and
|
· |
add
value to the “bottom-line” by helping to diminish product diversion and
counterfeiting.
|
· |
continuing
to improve and customize our solution to meet our potential customers’
needs;
|
· |
continuing
to develop and enhance our existing DNA marker authentication
technologies;
|
· |
expanding
our customer base both domestically and abroad by targeting high
volume
markets; and
|
· |
augmenting
our competitive position through strategic acquisitions and
alliances.
|
· |
Equity
issued with registration rights
|
· |
Warrant
liability
|
· |
Fair
value of intangible assets
|
Trade
secrets and developed technologies (Weighted average life of 7
years)
|
$
|
9,430,900
|
||
Patents
(Weighted average life of 5 years)
|
34,257
|
|||
Total
Amortized identifiable intangible assets-Gross carrying value:
|
$
|
9,465,157
|
||
Less:
|
||||
Accumulated
Amortization
|
(1,980,664
|
)
|
||
Impairment
|
(5,655,011
|
)
|
||
Net:
|
$
|
1,829,482
|
||
Residual
value:
|
$
|
0
|
2007
|
$
|
277,982
|
||
2008
|
370,642
|
|||
2009
|
365,504
|
|||
2010
|
363,791
|
|||
2011
and thereafter
|
451,563
|
|||
Total
|
$
|
1,829,482
|
· |
availability,
quality and price relative to competitive solutions;
|
· |
customers’
opinions of the solutions’ utility;
|
· |
ease
of use;
|
· |
consistency
with prior practices;
|
· |
scientists’
opinions of the solutions’
usefulness;
|
· |
citation
of the solutions in published research;
and
|
· |
general
trends in anti-counterfeit and security solutions’ research.
|
· |
product
performance, features and liability;
|
· |
price;
|
· |
timing
of product introductions;
|
· |
ability
to develop, maintain and protect proprietary products and technologies;
|
· |
sales
and distribution capabilities;
|
· |
technical
support and service;
|
· |
brand
loyalty;
|
· |
applications
support; and
|
· |
breadth
of product line.
|
· |
operations
and financial systems;
|
· |
procedures
and controls; and
|
· |
training
and management of our employees.
|
· |
difficulties
in staffing, managing and integrating international operations due
to
language, cultural or other
differences;
|
· |
different
or conflicting regulatory or legal
requirements;
|
· |
foreign
currency fluctuations; and
|
· |
diversion
of significant time and attention of our
management.
|
· |
that
a broker or dealer approve a person’s account for transactions in penny
stocks; and
|
· |
the
broker or dealer receive from the investor a written agreement to
the
transaction, setting forth the identity and quantity of the penny
stock to
be purchased.
|
· |
obtain
financial information and investment experience objectives of the
person;
and
|
· |
make
a reasonable determination that the transactions in penny stocks
are
suitable for that person and the person has sufficient knowledge
and
experience in financial matters to be capable of evaluating the risks
of
transactions in penny stocks.
|
· |
sets
forth the basis on which the broker or dealer made the suitability
determination; and
|
· |
that
the broker or dealer received a signed, written agreement from the
investor prior to the transaction.
|
· |
accounting
for and disclosing the fair value of warrants and options to acquire
our
common stock issued to non-employees as a current period
expense;
|
· |
accounting
for and disclosing the fair value of shares issued to a former Director
in
exchange for previously incurred
debt;
|
· |
accounting
for and disclosing the fair value of warrants issued to note holders
and
consultants having registration rights;
and
|
· |
accounting
for and disclosing the revaluation for warrant liabilities as of
each
reporting period.
|
· |
We
reviewed all convertible securities to identify any securities that
may
have embedded beneficial conversion features or derivatives;
and
|
· |
We
have improved the supervision and training of our accounting staff
to
understand and implement applicable accounting requirements, policies
and
procedures applicable to the accounting and disclosure of convertible
securities and derivatives.
|
MATTER
|
FOR
|
AGAINST/WITHHELD
|
ABSTAINED
|
(1)
Election of Directors:
|
|||
James
A. Hayward
|
68,129,155
|
145,708
|
|
Yacov
Shamash
|
68,129,023
|
145,840
|
|
Jun-Jei
Sheu
|
66,493,485
|
1,781,378
|
|
Sanford
R. Simon
|
67,799,163
|
475,700
|
|
(2)
Ratification of Auditors
|
67,895,259
|
249,050
|
130,554
|
(3)
Ratification and Approval of the Charter Amendment
|
64,915,372
|
3,326,883
|
32,607
|
(4)
Ratification and Approval of the Charter Amendment
|
44,010,949
|
2,904,837
|
127,756
|
3(i)1
|
Articles
of Incorporation of Applied DNA Sciences, Inc. as amended, filed
herewith.
|
3(i)2 | Certificate of Designation , Powers, Preferences and Rights of the Founders' Series of Convertible Preferred Stock, filed herewith. |
10.1
|
Joint
Development and Marketing Agreement, dated April 18, 2007 by and
between
Applied DNA Sciences and International Imaging Materials, Inc. filed
as an
exhibit to the current report on Form 8-K filed with the SEC on April
24,
2007 and incorporated herein by
reference.
|
10.2
|
Technology
Reseller Agreement, dated May 30, 2007 by and between Applied DNA
Sciences
and Printcolor Screen Ltd. filed as an exhibit to the current report
on
Form 8-K filed with the SEC on June 1, 2007 and incorporated herein
by
reference.
|
10.3
|
Feasibility
Study Agreement, dated June 27, 2007 by and between Applied DNA Sciences
and Supima filed as an exhibit to the current report on Form 8-K
filed
with the SEC on July 3, 2007 and incorporated herein by
reference.
|
31.1
|
Certification
of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a),
promulgated under the Securities and Exchange Act of 1934, as
amended.
|
31.2
|
Certification
of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a),
promulgated under the Securities and Exchange Act of 1934, as
amended.
|
32.1
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
the Sarbanes-Oxley Act of 2002 (Chief Executive
Officer).
|
32.2
|
Certification
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
the Sarbanes-Oxley Act of 2002 (Chief Financial
Officer).
|
Date:
August 20, 2007
|
By:
/s/ JAMES A. HAYWARD
|
James
A. Hayward
|
|
Chief
Executive Officer (Principal Executive Officer, Principal
Financial
Officer and Principal Accounting
Officer)
|